(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.25%.
Aldeyra Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ALDX's revenue for 2025 to be $5,377,958,466, with the lowest ALDX revenue forecast at $1,244,328,349, and the highest ALDX revenue forecast at $9,511,588,582. On average, 3 Wall Street analysts forecast ALDX's revenue for 2026 to be $4,570,458,629, with the lowest ALDX revenue forecast at $985,192,791, and the highest ALDX revenue forecast at $9,553,384,640.
In 2027, ALDX is forecast to generate $3,960,833,272 in revenue, with the lowest revenue forecast at $2,394,317,025 and the highest revenue forecast at $6,473,015,180.